FDA shoots down petition to stall generic versions of Bristol Myers' blockbuster chemo Abraxane
Five years after Bristol Myers Squibb’s Celgene filed a petition with the FDA as part of an attempt to delay the launch of generic versions …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
